Payment overview · 2025
General Payments
$420.23
19 reported records · 11 companies
Healthcare provider profile · identity verified
Riaz Ul Haque, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PEARLAND, TX · NPI 1881697852
Verified facts
What the public records show
CMS Open Payments records show Riaz Ul Haque, M.D. received $420.23 in general payments during 2025 across 19 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.73 | 20.4% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.62 | 18.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.69 | 12.8% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $47.85 | 11.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.78 | 9.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $26.64 | 6.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.29 | 4.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.85 | 4.5% | 1 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $18.07 | 4.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.34 | 3.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.37 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $420.23 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $85.73 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $77.62 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $53.69 | 3 | 2025 |
Source payment records
|
|||||
| MAKO Normalized: mako |
Device | Stryker Corporation | $47.85 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.78 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| TEMPUS PIXEL Normalized: tempus pixel |
Device | Tempus AI, Inc | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 60 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 47 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 764 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 438 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 413 | 130 |
| Losartan Potassium | Losartan Potassium | 384 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 368 | 94 |
| Metformin Hcl | Metformin Hcl | 355 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 343 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 325 | 88 |
| Alendronate Sodium | Alendronate Sodium | 320 | 95 |
| Montelukast Sodium | Montelukast Sodium | 308 | 98 |
| Omeprazole | Omeprazole | 277 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 218 | 76 |
| Prednisone | Prednisone | 215 | 158 |
| Meloxicam | Meloxicam | 211 | 122 |
| Gabapentin | Gabapentin | 209 | 66 |
| Lisinopril | Lisinopril | 209 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 62 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 190 | 75 |
| Finasteride | Finasteride | 182 | 49 |
| Cefdinir | Cefdinir | 178 | 132 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 48 |
| Fenofibrate | Fenofibrate Nanocrystallized | 162 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 158 | 56 |
| Ozempic | Semaglutide | 144 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 35 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 141 | 34 |
| Trazodone Hcl | Trazodone Hcl | 139 | 36 |
| Azithromycin | Azithromycin | 131 | 105 |
| Carvedilol | Carvedilol | 128 | 37 |
| Tramadol Hcl | Tramadol Hcl | 127 | 45 |
| Potassium Chloride | Potassium Chloride | 119 | 34 |
| Atenolol | Atenolol | 117 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 116 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 22 |
| Ezetimibe | Ezetimibe | 112 | 41 |
| Eliquis | Apixaban | 111 | 23 |
| Jardiance | Empagliflozin | 111 | 32 |
| Buspirone Hcl | Buspirone Hcl | 110 | 34 |
| Simvastatin | Simvastatin | 108 | 25 |
| Alprazolam | Alprazolam | 102 | 23 |
| Levetiracetam | Levetiracetam | 100 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 96 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 48 |
| Furosemide | Furosemide | 95 | 35 |
| Glipizide | Glipizide | 95 | 29 |
| Divalproex Sodium | Divalproex Sodium | 93 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 30 |
| Donepezil Hcl | Donepezil Hcl | 80 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 43 |
| Januvia | Sitagliptin Phosphate | 78 | 19 |
| Sertraline Hcl | Sertraline Hcl | 75 | 16 |
| Repaglinide | Repaglinide | 73 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 58 |
| Methylprednisolone | Methylprednisolone | 72 | 47 |
| Oxybutynin Chloride | Oxybutynin Chloride | 68 | 12 |
| Allopurinol | Allopurinol | 67 | 21 |
| Doxepin Hcl | Doxepin Hcl | 67 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 18 |
| Latanoprost | Latanoprost | 63 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 63 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 60 | 18 |
| Famotidine | Famotidine | 59 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 24 |
| Sucralfate | Sucralfate | 57 | 22 |
| Tradjenta | Linagliptin | 57 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 36 |
| Clonidine | Clonidine | 55 | 24 |
| Labetalol Hcl | Labetalol Hcl | 55 | 11 |
| Memantine Hcl | Memantine Hcl | 54 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 14 |
| Terazosin Hcl | Terazosin Hcl | 52 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 50 | 12 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Pregabalin | Pregabalin | 50 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 49 | 17 |
| Ketoconazole | Ketoconazole | 48 | 12 |
| Linzess | Linaclotide | 47 | 14 |
| Topiramate | Topiramate | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 44 | 12 |
| Meclizine Hcl | Meclizine Hcl | 43 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 28 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 42 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 42 | 12 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Trulicity | Dulaglutide | 39 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 14 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 12 |
| Fluconazole | Fluconazole | 32 | 22 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 17 |
| Temazepam | Temazepam | 27 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Travoprost | Travoprost | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 21 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 19 |
| Naltrexone Hcl | Naltrexone Hcl | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 20 |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | 11 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Digoxin | Digoxin | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Baclofen | Baclofen | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $420.23 · 19 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AREXVY, CREON, FARXIGA, FREESTYLE LIBRE 3, Kerendia, LINZESS, Leqembi, MAKO, MOUNJARO, OTEZLA, REPATHA, TEMPUS PIXEL, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error